Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the paraganglioma market grown in recent years?

The market size for paraganglioma has seen substantial growth recently. The market is predicted to expand from a value of $2.89 billion in 2024 to $3.03 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.0%. The ascent witnessed in the past can be linked to enhancements in diagnostic imaging, rise in awareness and screening initiatives, approval of targeted therapies by regulatory bodies, expansion of specialized treatment facilities, and progress in genetic testing.

How is the paraganglioma market size expected to evolve during the forecast period?

Anticipations are high for the paraganglioma market value to experience robust expansion in the upcoming years. The projections suggest that by 2029, the market will increase to a worth of $3.64 billion, growing at a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the forecast period encompass the emergence of specific targeted therapies & immunotherapies, the widening of radiopharmaceuticals, escalated prevalence of genetic diseases, increased investment in research on uncommon diseases and enhanced healthcare accessibility in developing markets. Major trends shaping this period include progress in targeted treatments, the expansion of radiopharmaceuticals, the surge in adoption of immunotherapy strategies, improvement in the application of artificial intelligence (AI) in diagnostic procedures, and advancements in minimal invasive surgical procedures.

Get your paraganglioma market report here!

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Which key drivers are propelling the paraganglioma market’s growth?

The surge in funds dedicated to oncology research and treatment is anticipated to drive growth in the paraganglioma market. This funding comes from a variety of sources such as governments, pharmaceutical corporations, research organizations, and private investors who are committed to enhancing our comprehension of cancer, as well as improving its prevention, diagnosis, and treatment methods. The boost in oncology funding comes as a response to the escalating global cancer burden and innovations in precision medicine, a growing demand for fresh therapy options, extensive clinical trials, financial backing from public and private sectors, and the emergence of targeted and immunotherapy treatments. These funds not only contribute to the progression of early diagnosis of paraganglioma but also aid in expanding treatment choices such as targeted therapies and immunotherapy, investing in clinical trials for potent drugs, strengthening pediatric cancer care infrastructure, and promoting avant-garde research to familiarize with the disease’s biology and progress. For example, IQVIA, an Indian IT firm offering advanced analytics, noted that global spending on cancer treatment escalated to $223 billion in 2023, a $25 billion surge from 2022, and it’s projected to skyrocket to $409 billion by 2028. Consequently, this increase in financial support for oncology research and treatment is fuelling the paraganglioma market.

What are the market segments in the paraganglioma industry?

The paraganglioma market covered in this report is segmented –

1) By Type: Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Paragangliomas

2) By Origin: Head And Neck, Abdomen, Pelvis, Other Origins

3) By Treatment Type: Peptide Receptor Radionuclide Therapy, Surgery, Chemotherapy, Radiation Therapy, Other Treatment Types

4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas, Extra-Adrenal Sympathetic Paragangliomas

2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas, Thoracic Parasympathetic Paragangliomas

3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas, Bilateral Carotid Paragangliomas

4) By Cervical Paragangliomas: Vagal Paragangliomas, Hypoglossal Paragangliomas

5) By Jugular Paragangliomas: Type A, Type B, Type C, Type D

6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas, Non-Catecholamine-Secreting Paragangliomas

7) By Temporal Paragangliomas: Tympanic Paragangliomas, Mastoid Paragangliomas

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21245&type=smp

Which leading companies are shaping the growth of the paraganglioma market?

Major companies operating in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc. , Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children’s Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome , National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute

Which trends are expected to transform the paraganglioma market?

Prominent businesses functioning in the paraganglioma market are concentrating on the invention of innovative therapies like oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors that provide specific therapy alternatives for paraganglioma patients. The oral HIF-2a inhibitor is a specialized therapy that controls HIF-2a activity, a primary element in tumour growth under deficient oxygen situations, aiding in decelerating the progress of cancers such as paraganglioma. For example, in January 2025, Merck, an American biopharmaceutical firm, stated that its supplemental new drug application for Welireg (belzutifan) had been prioritized for review by the U.S. Food and Drug Administration (FDA), a US government agency. The medication is designed for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The sNDA is rooted in objective response rate (ORR) and duration of response (DOR) information garnered from the Phase 2 LITESPARK-015 trial.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21245

Which geographic areas are influencing the growth of the paraganglioma market?

North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paraganglioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chickenpox Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Monkey Pox Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monkey-pox-testing-global-market-report

Migraine Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/migraine-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: